CNTA CENTESSA PHARMACEUTICALS PLC revenue, earnings and financials

For the quarter ended March 31, 2026, CENTESSA PHARMACEUTICALS PLC reported revenue of $0 (down 100.0% from a year earlier), net income of −$79.2M and diluted EPS of −$0.52; over the last four quarters revenue was $0 and net income −$251M; for the fiscal year ended December 2025 revenue was $15.0M.

CNTA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $15.0M, gross profit n/a, operating income −$208M, net income −$198M (margin -1316.9%), EPS −$1.46
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$201M, net income −$236M (margin n/a), EPS −$2.06
• Fiscal year ended Dec 2023: revenue $6.85M, gross profit n/a, operating income −$171M, net income −$151M (margin -2204.7%), EPS −$1.57
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$212M, net income −$216M (margin n/a), EPS −$2.31
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$374M, net income −$381M (margin n/a), EPS −$5.07

CNTA quarterly revenue and earnings

• Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$79.2M, EPS −$0.52
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$66.2M, EPS −$0.47
• Quarter ended Sep 30, 2025: revenue $0, net income −$54.9M, EPS −$0.41
• Quarter ended Jun 30, 2025: revenue $0, net income −$50.3M, EPS −$0.38
• Quarter ended Mar 31, 2025: revenue $15.0M, net income −$26.1M, EPS −$0.20
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$111M, EPS −$0.91
• Quarter ended Sep 30, 2024: revenue $0, net income −$42.6M, EPS −$0.37
• Quarter ended Jun 30, 2024: revenue $0, net income −$43.8M, EPS −$0.40
• Quarter ended Mar 31, 2024: revenue $0, net income −$38.0M, EPS −$0.38
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$36.8M, EPS −$0.38
• Quarter ended Sep 30, 2023: revenue n/a, net income −$38.6M, EPS −$0.40
• Quarter ended Jun 30, 2023: revenue n/a, net income −$24.9M, EPS −$0.26
• Quarter ended Mar 31, 2023: revenue n/a, net income −$50.7M, EPS −$0.53
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$43.2M, EPS −$0.45
• Quarter ended Sep 30, 2022: revenue n/a, net income −$53.9M, EPS −$0.57
• Quarter ended Jun 30, 2022: revenue n/a, net income −$64.7M, EPS −$0.69
• Quarter ended Mar 31, 2022: revenue n/a, net income −$54.5M, EPS −$0.60
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$60.8M, EPS $1.00
• Quarter ended Sep 30, 2021: revenue n/a, net income −$40.2M, EPS −$0.45
• Quarter ended Jun 30, 2021: revenue n/a, net income −$41.5M, EPS −$0.65

CNTA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$194M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$142M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$160M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$201M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$135M, share buybacks $12.0K

CNTA balance sheet

• Mar 31, 2026: cash $62.4M, total assets $642M, total liabilities $154M, shareholders' equity $487M, long-term debt $110M
• Dec 31, 2025: cash $61.3M, total assets $687M, total liabilities $161M, shareholders' equity $527M, long-term debt $110M
• Sep 30, 2025: cash $50.8M, total assets $448M, total liabilities $147M, shareholders' equity $302M, long-term debt $110M
• Jun 30, 2025: cash $44.2M, total assets $492M, total liabilities $147M, shareholders' equity $345M, long-term debt $110M
• Mar 31, 2025: cash $105M, total assets $528M, total liabilities $142M, shareholders' equity $386M, long-term debt $109M
• Dec 31, 2024: cash $383M, total assets $577M, total liabilities $175M, shareholders' equity $402M, long-term debt $109M
• Sep 30, 2024: cash $395M, total assets $610M, total liabilities $111M, shareholders' equity $499M, long-term debt $75.7M
• Jun 30, 2024: cash $127M, total assets $399M, total liabilities $112M, shareholders' equity $287M, long-term debt $76.5M

What is CNTA's revenue?

CENTESSA PHARMACEUTICALS PLC reported $0 of revenue over its last four quarters, through March 31, 2026.

Is CNTA profitable?

No. CENTESSA PHARMACEUTICALS PLC lost $251M over the last four quarters.

What is CNTA's EPS?

Diluted earnings per share over the last four quarters were −$1.78; −$0.52 in the latest quarter.

CNTA ownership and insider trades · All stocks